Weight Loss Injections and Breast Cancer: What the Evidence Shows

Do GLP-1 medicines increase breast cancer risk?

This is a question our prescribers hear most weeks, and it deserves a straight answer. As of mid-2026, neither the MHRA, NHS England nor NICE has identified breast cancer as a safety signal linked to tirzepatide (Mounjaro) or semaglutide (Wegovy) use for weight management. The medicines' summary documents and the published clinical trial programmes do not list breast cancer as a known adverse effect. Large studies such as SURMOUNT-1 for tirzepatide and STEP 1 for semaglutide, both involving thousands of adults over 68 to 72 weeks, recorded adverse event data carefully, and no elevated breast cancer incidence emerged that prompted a regulatory response. That said, longer-term post-marketing surveillance is ongoing, and the research picture continues to develop. The GLP-1 receptor is present in a range of tissues, and scientists are studying how receptor activation might interact with different cell types, but at present, no causal link to breast cancer has been established in humans. The broader question of weight loss injections and cancer is addressed in more detail elsewhere on this site, and the honest answer there is the same: current evidence does not support a causal connection, but research is continuing and prescribers should always know your full history.

Does obesity affect breast cancer risk, and could losing weight change that?

This context matters. Excess body weight is a well-documented risk factor for several cancers, including breast cancer, particularly oestrogen-receptor-positive breast cancer in postmenopausal women, partly because adipose tissue produces oestrogen. The NHS notes that being overweight or obese raises cancer risk, and this relationship is one reason clinicians consider weight management an important component of long-term health, not just a lifestyle preference. Whether meaningful weight loss achieved with a GLP-1 medicine translates into a reduction in breast cancer risk is not yet confirmed by trial data specific to cancer outcomes. Observational research is promising but not yet definitive. What is established is that reducing body weight has measurable benefits across a range of metabolic and hormonal markers. A prescriber reviewing your case will weigh these broader considerations (not just the number on the scale) before recommending a treatment. For a fuller picture of how these medicines relate to cancer risk more generally, including what the trials have and have not measured, that resource explains the landscape in plain terms.

What if I have a personal or family history of breast cancer?

A history of breast cancer, or a strong family history, is precisely the kind of information that belongs in your consultation. It does not automatically disqualify someone from receiving treatment, there is no blanket contraindication in the licensed prescribing guidance for Mounjaro or Wegovy that excludes people with a prior breast cancer history. However, individual circumstances vary considerably, and a prescriber needs to understand your treatment history, any hormonal therapy you may be taking, and whether you are under active oncological follow-up. That nuanced picture cannot be captured by an algorithm. At nume, every consultation is read by a GPhC-registered Independent Prescriber personally, on the same day it is submitted. If your situation is complex, they will ask for more detail or advise that treatment is not suitable right now. It is also worth noting that women using oral contraceptives while taking tirzepatide are advised to add a non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because absorption of oral medicines may be affected, a consideration that intersects with some hormone-based cancer prevention plans. The specific question of these medicines and breastfeeding is covered separately, since that carries distinct guidance. If cancer-drug interactions or ongoing oncological care are part of your picture, the prescriber may recommend you discuss the decision with your oncologist or GP first. That is good clinical practice, and it is the kind of joined-up approach the clinical team at nume takes seriously. Women who are currently pregnant or breastfeeding, or who are actively trying to conceive, are not recommended to use these medicines in any circumstance.

Where does this leave you if you are considering treatment?

The evidence available today does not point to GLP-1 weight loss injections raising breast cancer risk, and the case for treating significant obesity has clear health benefits across multiple conditions. For people with a breast cancer history or active breast disease, the right path is a properly conducted clinical assessment rather than a self-made decision either way. The general overview of weight loss injections sets out how these medicines work and who they are licensed for, which is useful background before a consultation. If you would like to explore your options, you can find out more about the treatments we offer at nume, including the consultation process. You might also find it helpful to read about weight loss injections and cancer more broadly, or (if thyroid history is also relevant) the thyroid cancer and GLP-1 medicines page, which covers a separate but frequently raised concern. The NHS provides guidance on managing weight as part of overall health on its obesity treatment page, and that is a sound starting point for understanding where medicines fit within a broader plan.